IHAM
NKTR icon

Integral Health Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Integral Health Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,000
Closed -$1.62M – 70
2019
Q4 		$1.62M Buy
+5,000
New +$1.45M 0.63% 42

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Integral Health Asset Management's NKTR Position: Q1 2020 in Review

Integral Health Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 5,000 shares — an estimated $1.62M sold.

Integral Health Asset Management first reported a position in NKTR in Q4 2019 and held it in 1 quarter. The position peaked at $1.62M in Q4 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Integral Health Asset Management reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Integral Health Asset Management sold 5,000 Nektar Therapeutics shares in Q1 2020, an estimated $1.62M.
  • Integral Health Asset Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 1 quarter.
  • Integral Health Asset Management's Nektar Therapeutics position peaked at $1.62M in Q4 2019.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Integral Health Asset Management's 13F filing for Q1 2020, filed 15 May 2020.